Blood Collection Tube for Liquid Biopsy Market Records 19.6% CAGR Growth Outlook, Supported by Streck, QIAGEN, Greiner Bio-One

The global blood collection tube for liquid biopsy market is emerging as a critical enabling segment within the rapidly expanding precision diagnostics ecosystem, driven by rising adoption of non-invasive cancer testing, companion diagnostics, and molecular biomarker analysis.

According to Fact.MR, the global market for blood collection tubes used in liquid biopsy applications is estimated at USD 188.4 million in 2026 and is forecast to expand at a remarkable 19.6% CAGR, reaching approximately USD 1,128.0 million by 2036. The market includes:

Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=4495

Quick Stats Snapshot

Market Value (2026): USD 188.4 million
Projected Market Value (2036): USD 1.128 billion
Forecast CAGR (2026-2036): 19.6%
Core Applications: Oncology diagnostics, NIPT, molecular analysis, companion diagnostics
Leading Technologies: cfDNA stabilization, CTC preservation, multi-analyte collection systems
Primary End Users: Hospitals, molecular diagnostic labs, pharmaceutical companies, research institutes

According to Fact.MR, the global market for blood collection tubes used in liquid biopsy applications is estimated at USD 188.4 million in 2026 and is forecast to expand at a remarkable 19.6% CAGR, reaching approximately USD 1,128.0 million by 2036. The market includes:

Cell-free DNA (cfDNA) stabilization tubes
Circulating tumor cell (CTC) collection tubes
Multi-analyte stabilization systems
Molecular analysis blood collection platforms

Growth is being fueled by expanding clinical use of liquid biopsy in oncology, rising FDA-cleared assay approvals, and increasing pharmaceutical investment in biomarker-driven therapies.

Market Size and Strategic Outlook

Blood collection tubes for liquid biopsy are highly specialized specimen collection systems engineered to preserve:

Circulating tumor DNA (ctDNA)
Cell-free DNA (cfDNA)
Circulating tumor cells (CTCs)
RNA biomarkers
Extracellular vesicles

during transport, storage, and molecular analysis.

Unlike conventional blood tubes, these systems are designed to:

Prevent nucleic acid degradation
Minimize white blood cell contamination
Extend sample stability windows
Improve assay reproducibility

These capabilities are becoming increasingly important as liquid biopsy expands into:

Oncology screening
Minimal residual disease (MRD) monitoring
Treatment response assessment
Prenatal diagnostics
Multi-cancer early detection (MCED) platforms.

The market is evolving from a niche research-support segment into a strategic component of precision medicine infrastructure.

Key Growth Drivers

1. Rapid Expansion of Liquid Biopsy in Oncology

Liquid biopsy adoption is accelerating because it offers:

Minimally invasive testing
Real-time tumor monitoring
Repeatable sampling capability
Faster diagnostic workflows

Compared with conventional tissue biopsies, liquid biopsy reduces:

Patient discomfort
Surgical risk
Sampling limitations

Demand is rising rapidly in:

Lung cancer
Breast cancer
Colorectal cancer
Prostate cancer diagnostics.

As assay sensitivity improves, blood collection tube quality is becoming increasingly critical to ensuring accurate biomarker preservation.

2. Growth of Precision Medicine and Companion Diagnostics

Targeted cancer therapies increasingly rely on:

Biomarker-guided treatment selection
Mutation monitoring
Molecular profiling

Pharmaceutical companies are expanding investment in companion diagnostics linked to:

Immunotherapy
Personalized oncology drugs
Genomic sequencing platforms

This directly supports demand for advanced liquid biopsy specimen collection systems.

3. Rising FDA Approvals and Clinical Acceptance

The liquid biopsy ecosystem has seen growing regulatory momentum, including FDA-cleared assays for several cancer indications.

Clinical adoption is increasing across:

Academic cancer centers
Hospital laboratories
Commercial molecular diagnostics providers

Standardized blood collection systems are essential for:

Regulatory compliance
Clinical reproducibility
Laboratory workflow consistency

4. Expansion of Non-Invasive Prenatal Testing (NIPT)

Liquid biopsy collection technologies are also being increasingly used in:

Prenatal genetic testing
Fetal chromosomal screening
Maternal-fetal diagnostics

NIPT adoption is rising globally because of:

Improved diagnostic accuracy
Reduced procedural risk
Growing prenatal healthcare awareness.
Market Challenges
Pre-Analytical Variability Risks

Liquid biopsy testing is highly sensitive to:

Sample handling errors
Temperature exposure
Delayed processing
Biomarker degradation

This creates strong demand for advanced stabilization technologies but also increases product development complexity.

High Validation and Regulatory Requirements

Manufacturers must demonstrate:

Biomarker stability performance
Assay compatibility
Clinical reproducibility
Regulatory compliance

Validation timelines and regulatory costs remain substantial barriers for newer entrants.

Limited Standardization Across Platforms

Differences in:

Collection methods
Preservation chemistries
Assay protocols

can create interoperability challenges between diagnostic platforms and laboratory systems.

Emerging Opportunities
Multi-Cancer Early Detection (MCED)

MCED blood tests represent one of the largest future opportunities in precision oncology.

These platforms aim to detect:

Multiple cancer types
Early-stage disease
Minimal tumor burden

through a single blood draw.

As MCED adoption grows, demand for highly stable blood collection systems is expected to surge.

AI and Machine Learning Integration

Artificial intelligence is increasingly being integrated into:

Biomarker interpretation
ctDNA analysis
CTC identification
Predictive oncology workflows.

Improved sample quality from advanced collection tubes enhances AI model reliability and clinical performance.

Pharmaceutical Clinical Trials and Drug Development

Pharmaceutical companies are increasingly incorporating liquid biopsy into:

Oncology trials
Treatment monitoring
Drug response analysis
Minimal residual disease studies

This is creating strong demand for standardized molecular specimen collection products.

Emerging Market Expansion

Asia-Pacific healthcare systems are rapidly expanding:

Cancer screening infrastructure
Precision medicine programs
Molecular diagnostics laboratories

China, Japan, South Korea, and India are expected to become major growth markets.

Segmentation Insights

By Product Type

cfDNA stabilization tubes: Largest and fastest-growing segment
CTC collection tubes
cfRNA tubes
Multi-analyte stabilization tubes

cfDNA systems dominate because of their central role in oncology liquid biopsy testing.

By Application

Cancer diagnosis and monitoring: Largest segment
Non-invasive prenatal testing (NIPT)
Research applications
Infectious disease diagnostics

Oncology remains the primary revenue driver because of expanding liquid biopsy adoption in precision cancer care.

By End User

Hospitals and diagnostic laboratories
Research institutes
Pharmaceutical and biotechnology companies
Academic medical centers

Large centralized diagnostic laboratories continue to dominate high-volume liquid biopsy processing.

Regional Analysis

North America: Largest Market

The United States leads the market due to:

Strong oncology diagnostics infrastructure
High liquid biopsy adoption
Presence of major diagnostics companies
FDA regulatory advancement.

North America also benefits from:

Large-scale precision medicine investment
High cancer screening expenditure
Strong clinical trial activity
Europe: Regulation and Research Driven

European demand is supported by:

Advanced oncology research networks
Growing liquid biopsy reimbursement
Strong molecular diagnostics adoption

Germany, France, and the United Kingdom remain leading regional markets.

Asia-Pacific: Fastest Growth Region

Asia-Pacific is expected to record the fastest growth due to:

Rising cancer incidence
Expanding biotechnology sectors
Government precision medicine initiatives
Rapid healthcare modernization.

China and Japan are emerging as major innovation hubs for liquid biopsy technologies.

Competitive Landscape

The market remains innovation-intensive, with diagnostics and life sciences companies competing through:

Biomarker stabilization performance
Extended sample stability
Molecular assay compatibility
Automation integration

Key companies include:

Thermo Fisher Scientific
QIAGEN
Roche Diagnostics
Bio-Rad Laboratories
Streck
Greiner Bio-One

Competition increasingly centers on:

Biomarker preservation quality
Clinical validation
Multi-analyte compatibility
Global regulatory compliance
Strategic Implications for Industry Stakeholders
Invest in Advanced Stabilization Technologies: Sample integrity remains the core competitive differentiator
Align with Precision Oncology Ecosystems: Companion diagnostics partnerships will drive long-term growth
Expand Regulatory and Clinical Validation: FDA-aligned systems will gain stronger market positioning
Strengthen Pharma and Lab Partnerships: Integrated workflow compatibility is becoming essential

Future Outlook

The blood collection tube for liquid biopsy market is expected to become a foundational component of the next-generation diagnostics infrastructure over the next decade.

Industry evolution will likely focus on:

Multi-cancer early detection support
AI-enabled molecular diagnostics
Universal biomarker stabilization platforms
Home-based and decentralized testing workflows
Integrated precision medicine ecosystems

As oncology increasingly shifts toward non-invasive, data-driven disease management, blood collection technologies will become strategically important not only for diagnostics companies, but also for pharmaceutical developers, healthcare providers, and precision medicine platforms globally.

Browse Full Report: https://www.factmr.com/report/4495/blood-collection-tubes-for-liquid-biopsy-market

Executive Takeaways:

The market is projected to grow from USD 188.4 million in 2026 to USD 1.128 billion by 2036, at a robust 19.6% CAGR.

Growth is driven by precision oncology, liquid biopsy adoption, FDA-cleared assays, and companion diagnostics expansion.

cfDNA stabilization tubes remain the leading product category.
North America leads the market, while Asia-Pacific represents the fastest-growing regional opportunity.

Competitive advantage increasingly depends on sample stabilization quality, assay compatibility, regulatory validation, and integration into precision medicine workflows.

Unlock 360° Insights for Strategic Decision Making and Investment Planning : https://www.factmr.com/checkout/4495

Related Reports:

Blood Thawing System Market: https://www.factmr.com/report/blood-thawing-system-market

Blood Glucose Testing Devices Market: https://www.factmr.com/report/2681/blood-glucose-testing-devices-market

Blood Testing Devices Market: https://www.factmr.com/report/2680/blood-testing-devices-market

Blood-based Biomarker for Sports Medicine Market: https://www.factmr.com/report/blood-based-biomarker-for-sports-medicine-market

Contact:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

About Fact.MR

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.